Stem cell transplantations in patients with malignant lymphoma: Costs in a Dutch University Hospital in the period 1984-1995

Journal of Hematotherapy and Stem Cell Research

Volumn 8, Issue 6, 1999, Pages 619-625

  Uyl De Groot, C A ^a   Ossenkoppele, G J ^b   Buijt, I ^a   Huijgens, P C ^b  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CYTARABINE; ETOPOSIDE; MELPHALAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD TRANSFUSION; COST BENEFIT ANALYSIS; HOSPITALIZATION; HUMAN; LEUKAPHERESIS; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; NETHERLANDS; NONHODGKIN LYMPHOMA; PARENTERAL NUTRITION; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD CELL COUNT; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CARMUSTINE; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITAL COSTS; HOSPITAL UNITS; HOSPITALIZATION; HUMANS; LENGTH OF STAY; LYMPHOMA, NON-HODGKIN; MELPHALAN; NETHERLANDS; PARENTERAL NUTRITION; PATIENT ISOLATION; PODOPHYLLOTOXIN; PREDNISONE; RETROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS; VINCRISTINE;

EID: 0033427553     PISSN: 15258165     EISSN: None     Source Type: Journal    
DOI: 10.1089/152581699319786     Document Type: Article

References (19)

1. The International Non-Hodgkin's Lymphoma Project (1993). A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994.
2. Coiffier B, C Gisselbrecht, JM Vose, et al. (1991). Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Group d'Etudes des Lymphomes Agressifs. J Clin Oncol 9:211-219.
3. Armitage JO, DD Weisenburger, M Hutchins, et al. (1986). Chemotherapy for diffuse large-cell lymphoma - rapidly responding patients have more durable remissions. J Clin Oncol 4:160-164.
4. Vose JM, and JO Armitage. (1993). Role of autologous bone marrow transplantation in non-Hodgkin's lymphoma. Hematol Oncol Clin North Am 7:577-590.
5. Fisher RI, ER Gaynor, S Dahlberg, et al. (1994). A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate-or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study. Ann Oncol 5 (Suppl 2):91-95.
6. Cooper IA, MM Wolf, TI Robertson, et al. (1994). Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group. J Clin Oncol 12:769-778.
7. Philip T, C Guglielmi, A Hagenbeek, et al. (1995). Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545.
8. Kessinger A, JO Armitage, DM Smith, et al. (1989). High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma. Blood 74: 1260-1265.
9. Advani R, NJ Chao, SJ Homing, et al. (1992). Granulocyte macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hemopoietic stem cell transplantation for lymphoma. Ann Intern Med 116:183-189.
10. + hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor. Blood 74:1905-1914.
11. Uyl-de Groot CA, DJ Richel and FFH Rutten. (1994). Peripheral blood progenitor cell transplantation mobilised by r-met-HuG-CSF (filgrastim); a less costly alternative to autologous bone marrow transplantation. Eur J Cancer 30A: 1631-1635.
12. Ossenkoppele GJ, GJ Schuurhuis, AR Jonkhoff, et al. (1996). G-CSF (filgrastim)-stimulated whole blood kept unprocessed at 4° does support a BEAM-like regimen in bad-risk lymphoma. Bone Marrow Transplant 18:427-431.
13. Child JA, DL Barnard, SC Cartwright, et al. (1983). A pilot study of cyclical chemotherapy with high-dose methotrexate and CHOP (MTX-CHOP) in poor prognosis non-Hodgkin's lymphoma (NHL). Cancer Chemother Pharmacol 11:153-158.
14. Gomez GA, M Barcos, T Han and ES Henderson. (1987). Cyclophosphamide, vincristine, adriamycin and prednisone (CHOP) with and without intermediate dose methotrexate for the treatment of non-Hodgkin's lymphomas of diffuse histology. Cancer 60:18-24.
15. Kreuk AM de, GJ Ossenkoppele, CJLM Meijer and PC Huijgens. (1996). Prognostic factors for survival of non-Hodgkin's lymphoma patients treated with high-dose chemotherapy and autologous bone marrow transplantation. Bone Marrow Transplant 17:963-971.
16. Uyl-de Groot CA, GJ Ossenkoppele, I Buijt and PC Huijgens. (1999). Costs of peripheral blood progenitor cell transplantation using whole blood mobilised by G-CSF (filgrastim) as compared to autologous bone marrow transplantation in non-Hodgkin's lymphoma. PharmacoEcon 15:305-311.
17. Peters WP, M Ross, JJ Vredenburgh, et al. (1994). The use of intensive clinic support to permit outpatient autologous bone marrow transplantation for breast cancer. Semin Oncol 4:25-31.
18. Weaver CH, L Schwartsberg, B Zhen, et al. (1997). High-dose chemotherapy and peripheral blood stem cell infusion in patients with non-Hodgkin's lymphoma: results of outpatient treatment in community cancer centers. Bone Marrow Transplant 20:753-760.
19. Jagannath S, DH Vesole, M Zhang, et al. (1997). Feasibility and cost-effectiveness of outpatient autotransplants in multiple myeloma. Bone Marrow Transplant 20:445-450.